Manufacturing & Process Development
Scaling Humanized Immune System Mouse Models: Optimize Your CD34+ Engraftment with High Quality Cells
Table of Contents CD34+ Humanized Immune System Mice MNC Cell Quality Assessment: Flow Cytometry Data from CGT Global Cell Viability Cell Purity Cell Count Sources of CD34+ Cells: Comparison Table for Bone Marrow and Cord Blood Bulk Isolated CD34+ for Humanized Mice About CGT Global and Additional Resources Frequently Asked Questions List of Abbreviations The…
For More InformationTop PBMC Suppliers for 2026: Fresh, Cryopreserved, and GMP-Grade Options Compared
Introduction Peripheral Blood Mononuclear Cells (PBMCs) are foundational to immunology, oncology, and cell therapy research. Whether they are used for functional assays, vaccine development, or discovery-stage therapeutic studies, PBMC quality directly impacts data accuracy and reproducibility. In 2026, researchers expect more than just availability. They look for documented donor screening, consistent viability, and responsive support.…
For More InformationBest Leukopak Suppliers for Cell Therapy in 2026: Pricing, Quality, and Turnaround Compared
Introduction When it comes to sourcing leukopaks for cell therapy or research, product quality is only half the story. Procurement delays, unanswered inquiries, and limited visibility can stall entire workflows. In 2026, speed and communication matter just as much as purity and yield. To help researchers, process developers, and procurement teams choose confidently, we reviewed…
For More InformationScaling Cell & Gene Therapy Development: How CGT Global Supports Research, Clinical Trials, and Commercialization
By Joanna Wirkus, PhD From RUO to cGMP, CGT Global delivers quality, consistency, and regulatory readiness to help researchers advance therapies from discovery to patients. Executive Summary CGT Global accelerates cell and gene therapy development from discovery to commercialization. By providing rapid and reliable access to high-quality RUO and cGMP-certified materials and operating FDA- and CLIA-certified…
For More InformationBaby KJ Makes Headlines as the First Infant to Receive Personalized CRISPR Gene Editing Therapy
Written by Joanna Wirkus, PhD May 15, 2025, NPR ’s Science Friday spotlighted Baby KJ, the first infant to receive a personalized CRISPR-based gene editing treatment. The segment explored the groundbreaking therapy, the condition it aims to treat, and the collaborative effort behind this historic milestone. Here’s a summary of the key points from the…
For More InformationFast-Track Your Therapy Pipeline with CGT Global’s Clinical Capabilities
By: Joanna Wirkus Despite exponential progress in the field of biology, inherited and preventable diseases continue to burden billions of people worldwide. Bridging the gap between laboratory discoveries and transformative clinical therapies remains a significant challenge, , and an urgent opportunity. High-quality biospecimens are foundational to this effort, enabling the advancement of cell and gene…
For More InformationCGT Sourcing Guide 2025: How to Build a Resilient Supply Chain Amid Tariff Pressures
By CGT Global The latest round of U.S. tariffs didn’t just shake up the headlines—it shook the very foundations of global pharma supply chains. And while most of the buzz has focused on traditional drugmakers, let’s be clear: cell and gene therapy manufacturers aren’t sitting this one out. For companies working with high-value, time-sensitive materials…
For More InformationHow to Improve Humanized Mouse Engraftment: CD34+ Cell Sourcing & Viability Tips
By: Joanna Wirkus Simple Steps to Significantly Improve Humanized Mice Engraftment Success Previously in “Overcoming Challenges with Animal Models in Research”, we covered why animal models with human immune systems have significantly improved the translation of preclinical findings into life-saving treatments. Successfully creating these advanced models for testing new therapies relies on high hematopoietic stem…
For More InformationCord Blood CD34+ Cells: High Viability for Humanized Mouse Models
By: Joanna Wirkus The Rise of Cord Blood CD34+ Cells in Humanized Mouse Models and Cell Therapy Innovation Scientists in the late 1980’s discovered that umbilical cord blood derived stem cells had high proliferative potential and tolerated cryopreservation and thawing (Broxmeyer, 1989). Building on this research, the first report of cord blood derived CD34+ human…
For More InformationBuffy Coat vs. Leukapheresis: Choosing the Right Cell Source for Your Research
By: Joanna Wirkus Choosing Between Buffy Coat and Leukapheresis: A Guide for Scientists When your research hinges on high-quality, primary immune cells, starting with the right biological material can make or break your experiment. One of the most common questions we hear from scientists is: Should I use buffy coat- or leukapheresis-derived cells? The answer…
For More Information